Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and ren...
Alternative Titles
Full title
Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2721072412
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2721072412
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/2022.10.04.510832
How to access this item
https://www.proquest.com/docview/2721072412?pq-origsite=primo&accountid=13902
